quinazolines has been researched along with panobinostat in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Khoueiry, A; Fazzone, W; LaBonte, MJ; Ladner, RD; Lenz, HJ; Louie, SG; Russell, J; Wilson, PM | 1 |
| Akar, A; Altiok, S; Bepler, G; Chiappori, A; Gray, JE; Haura, E; Kish, JA; Kreahling, J; Lush, R; Neuger, A; Pinder-Schenck, M; Schell, MJ; Tanvetyanon, T; Tetteh, L; Williams, CC; Zhao, X | 1 |
| Chen, KC; Chen, PC; Cheng, CH; Huang, YH; Lan, CH; Lee, WY; Lin, CW; Wu, HC; Wu, WS | 1 |
1 trial(s) available for quinazolines and panobinostat
| Article | Year |
|---|---|
A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Panobinostat; Quinazolines; Treatment Outcome | 2014 |
2 other study(ies) available for quinazolines and panobinostat
| Article | Year |
|---|---|
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; ErbB Receptors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lapatinib; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mutation; Neoplasm Transplantation; Panobinostat; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2011 |
Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ.
Topics: A549 Cells; Acyltransferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Hydroxamic Acids; Indoles; Mice; Panobinostat; Proto-Oncogene Proteins p21(ras); Quinazolines; Transcription Factors | 2017 |